Factors influencing the formation of new human coronary lesions: age, blood pressure, and blood cholesterol

W J Mack, D H Blankenhorn, W J Mack, D H Blankenhorn

Abstract

Background: The Cholesterol Lowering Atherosclerosis Study, a controlled angiographic trial, has reported that new native coronary artery lesions are significantly reduced by aggressive blood lipid lowering therapy with colestipol plus niacin. To study factors relevant to primary atherosclerosis prevention, we have conducted an epidemiologic analysis of new native coronary lesion formation in placebo-treated patients.

Methods: Univariate and multivariate logistic regression procedures were used to examine age at entry into the study, number of years since bypass, body weight, diastolic and systolic blood pressure, plasma total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, non-HDL-cholesterol, and apolipoproteins A-I,B, and C-III.

Results: Significant univariate protective factors were older age (P less than .006), reduction of total plasma cholesterol (P less than .040), and systolic (P less than .024) and diastolic (P less than .022) blood pressure. Significant multivariate protective factors were older age (P less than .005) and reduction in systotic blood pressure (P less than .021). Blood pressure effects were not associated with use of specific antihypertensive agents.

Conclusions: These data provide additional support for the control of hypertension and reduction of blood cholesterol level for primary and secondary ischemic heart disease prevention. They also indicate the existence of a population at high risk for early coronary lesion formation and the need for improved means to identify such individuals prior to the onset of clinical manifestations of ischemic heart disease.

References

    1. Br Med J (Clin Res Ed). 1984 Jul 28;289(6439):220-3
    1. J Am Coll Cardiol. 1984 Mar;3(3):659-67
    1. N Engl J Med. 1985 Mar 28;312(13):805-11
    1. Am J Cardiol. 1986 Jan 1;57(1):66-70
    1. Am J Epidemiol. 1986 Dec;124(6):903-15
    1. J Am Coll Cardiol. 1986 Dec;8(6):1325-31
    1. JAMA. 1987 Jun 19;257(23):3233-40
    1. Control Clin Trials. 1987 Dec;8(4):356-87
    1. JAMA. 1990 Mar 23-30;263(12):1646-52
    1. Clin Chem. 1972 Jun;18(6):499-502
    1. Lab Invest. 1973 Feb;28(2):252-62
    1. Circulation. 1973 Mar;47(3):455-64
    1. Am Heart J. 1973 Aug;86(2):165-72
    1. Am J Cardiol. 1974 Jan;33(1):7-11
    1. Am Heart J. 1975 May;89(5):591-8
    1. Am Heart J. 1977 Mar;93(3):327-33
    1. Am J Cardiol. 1978 Feb;41(2):216-20
    1. Circulation. 1979 Feb;59(2):199-211
    1. Am J Cardiol. 1979 Apr;43(4):699-707
    1. Circulation. 1981 Mar;63(3):527-36
    1. Lancet. 1982 Aug 14;2(8294):374-5
    1. Int J Cardiol. 1982;2(1):43-55
    1. Circulation. 1984 Feb;69(2):313-24
    1. Epidemiol Rev. 1984;6:140-66

Source: PubMed

3
Abonner